Advances in research of dual inhibitors targeting Janus kinase and histone deacetylase
10.16438/j.0513-4870.2024-0263
- VernacularTitle:基于Janus激酶和组蛋白去乙酰化酶的双靶点抑制剂研究进展
- Author:
Jing SHEN
1
;
Wei-jie HU
2
;
Guo-qiang DONG
1
;
Chun-quan SHENG
1
;
Ya-hui HUANG
1
Author Information
1. The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), Shanghai
2. School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou
- Publication Type:Research Article
- Keywords:
Janus kinase;
histone deacetylase;
ual-target inhibitor;
structure activity relationship;
pharmacophore
- From:
Acta Pharmaceutica Sinica
2024;59(11):3057-3073
- CountryChina
- Language:Chinese
-
Abstract:
Janus kinase (JAK) and histone deacetylase (HDAC) referred to as crucial targets in autoimmune diseases and cancers have achieved quite success in the treatment of these diseases. Until now, several JAK and HDAC inhibitors have been approved. Recently, developing single multi-targeting inhibitors including JAK/HDAC dual inhibitors based on network pharmacology has made significant progress in improving therapeutic efficacy, reducing toxic and side effects, and overcoming drug resistance. In this review, we summarize novel JAK/HDAC dual inhibitors as well as JAK/HDAC-based triple-targeting inhibitors, in order to provide reference for the discovery of novel JAK/HDAC dual inhibitor.
